Skip to main content

Carisma Therapeutics Announces Clinical & Preclinical Updates at 37th Annual SITC Meeting

Current TAP Partner


PHILADELPHIA – November 11, 2022 – Carisma Therapeutics Inc. (Carisma Therapeutics), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, presented today at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting additional findings from its CT-0508 chimeric antigen receptor macrophage (CAR-M) clinical trial for patients with advanced metastatic human epidermal growth factor receptor 2 (HER2) overexpressing solid tumors, supporting a favorable safety profile and manufacturing feasibility of its proprietary engineered cell therapy platform.

Details of Carisma Therapeutics’ data also accepted for presentation at the SITC 37th Annual Meeting:

Press Release